Enterprise-wide drug-drug interaction alerting system

Area of Science:

• Health Informatics
• Patient Safety
• Clinical Pharmacology

Background:

• Medical errors, including adverse drug events (ADEs), contribute significantly to patient mortality and morbidity.
• The Institute of Medicine's 1999 report highlighted the critical need for safer healthcare systems.
• Integrated delivery networks like Partners HealthCare System (PHS) are focused on enterprise-wide improvements in patient care.

Purpose of the Study:

• To develop and implement a drug-drug interaction (DDI) detection feature within existing clinical applications.
• To reduce the incidence of medication errors and prevent adverse drug events across PHS.
• To enhance patient safety through improved medication management systems.

Main Methods:

• Development of a DDI detection feature integrated into a suite of clinical applications.
• Implementation across major teaching institutions: Brigham & Women's Hospital (BWH) and Mass General Hospital (MGH).
• Deployment within various systems including NICU Order Entry (OE), pediatric and adult OE, The LMR, and BICS OE.

Main Results:

• A novel DDI detection feature has been successfully developed and integrated.
• The feature is being deployed across multiple critical clinical applications at BWH and MGH.
• This initiative represents a significant step towards enterprise-wide reduction of medication errors.

Conclusions:

• The implementation of a DDI detection feature is crucial for improving patient safety.
• Integrating such features into existing clinical workflows can effectively reduce adverse drug events.
• PHS's initiative demonstrates a commitment to leveraging technology for enhanced medication safety.